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Abstract
Introduction: Despite recent advances in the management of HIV infection and increased access to treatment, prevention, care
and support, the HIV/AIDS epidemic continues to be a major global health problem, with sub-Saharan Africa suffering by far the
greatest humanitarian, demographic and socio-economic burden of the epidemic. Information on HIV/AIDS clinical care and
established cohorts’ characteristics in the Central Africa region are sparse.
Methods: A survey of clinical care resources, management practices and patient characteristics was undertaken among 12 adult
HIV care sites in four countries of the International Epidemiologic Databases to Evaluate AIDS Central Africa (IeDEA-CA) Phase 1
regional network in October 2009. These facilities served predominantly urban populations and offered primary care in the
Democratic Republic of Congo (DRC; six sites), secondary care in Rwanda (two sites) and tertiary care in Cameroon (three sites)
and Burundi (one site).
Results: Despite some variation in facility characteristics, sites reported high levels of monitoring resources, including electronic
databases, as well as linkages to prevention of mother-to-child HIV transmission programs. At the time of the survey, there were
21,599 HIV-positive adults (median age37 years) enrolled in the clinical cohort. Though two-thirds were women, few adults
(6.5%) entered HIV care through prevention of mother-to-child transmission services, whereas 55% of the cohort entered care
through voluntary counselling and testing.Two-thirds of patients at sites in Cameroon and DRC were in WHO Stage III and IV at
baseline, whereas nearly all patients in the Rwanda facilities with clinical stage information available were in Stage I and II.WHO
criteria were used for antiretroviral therapy initiation. The most common treatment regimen was stavudine/lamivudine/
nevirapine (64%), followed by zidovudine/lamivudine/nevirapine (19%).
Conclusions: Our findings demonstrate the feasibility of establishing large clinical cohorts of HIV-positive individuals in a
relatively short amount of time in spite of challenges experienced by clinics in resource-limited settings such as those in this
region. Country differences in the cohort’s site and patient characteristics were noted. This information sets the stage for the
development of research initiatives and additional programs to enhance adult HIV care and treatment in Central Africa.
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Introduction
Despite the recent advances in the management of HIV
infection and the increased access to treatment, prevention,
care and support, the HIV/AIDS epidemic continues to be a
major global health problem [1]. Treatment regimens with
highly active antiretroviral therapy (HAART) have transformed
the infection to a manageable condition [2], and quantifiable
improvements in many indicators are evident due to the HIV/
AIDS programs internationally [3]. However, the epidemic
confers disproportionate humanitarian, demographic and
socio-economic impacts in certain areas of the world [4,5].
Sub-Saharan Africa suffers by far the greatest burden of
the epidemic [4,6], and this poses extreme pressures in
the affected countries’ capacities and human resources [7].
The scaling up of HAART [8,9] and voluntary HIV counselling
and testing (VCT) in combination with immediate antiret-
roviral therapy (ART) [10], as well as care delivery and
monitoring systemic improvements [11], have shown promis-
ing results. In spite of these great steps forward, enormous
and diverse challenges, such as late ART initiation and high
rates of loss to follow-up, still persist [1214].
In response to the ‘‘global imperative’’ created by the
epidemic [15,16], an unprecedented array of scientific and
financial resources has been mobilized, along with a global
political commitment expressed in the Millennium Develop-
ment Goals [17]. Long-lasting scientific initiatives [18,19]
in industrialized nations have advanced the current state of
knowledge and care of those with HIV infection and AIDS.
Divaris K et al. Journal of the International AIDS Society 2012, 15:17422
http://www.jiasociety.org/index.php/jias/article/view/17422 | http://dx.doi.org/10.7448/IAS.15.2.17422
1During the last decade, increased funding allocation was
made possible via major funders such as the US President’s
Emergency Plan for AIDS Relief (PEPFAR), The Global Fund to
Fight AIDS, Tuberculosis, and Malaria, and the World Bank.
These resources provided new opportunities for HIV/AIDS
prevention, treatment and care in low-resource regions [20].
This scaling-up created an immediate need for high-quality
research and implementation science to help inform the
scale-up process, as well as effective planning, monitoring
and evaluation of HIV/AIDS related programs, through
international collaborations [21,22]. In response, the Inter-
national Epidemiologic Databases to Evaluate AIDS (IeDEA)
was initiated in 2006 with funding from the US National
Institutes of Health (NIH), and the National Institute of
Allergy and Infectious Diseases (NIAID) to function as a
data harmonization and collaboration platform. The Eunice
Kennedy Shriver National Institute of Child Health and
Development (NICHD) provides additional support to con-
duct paediatric research, and the National Cancer Institute
(NCI) to initiate cancer-related research in Africa through the
IeDEA regional centres and affiliated sites. Currently, there
are seven funded IeDEA participating regions in five con-
tinents. The present paper describes the results of a survey
that was undertaken among the adult HIV care facilities of
the IeDEA-Central Africa (CA) Phase 1 network with the goals
of summarizing, comparing and presenting information on
clinical care resources, management practices and patient
characteristics within the regional network.
Methods
The IeDEA-CA network
The international research consortium of IeDEA (www.idea.
org) has established regional centres that monitor high-
quality data collection, entry and storage, in a uniform or
compatible manner across the seven regions: North America
[23], Latin America and Caribbean [24], Asia/Pacific, West
Africa, Central Africa, East Africa and Southern Africa. IeDEA
enables researchers around the world to address novel and
evolving research questions in HIV/AIDS that are currently
unanswerable by single cohorts. A description of the entire
IeDEA sub-Saharan Africa clinical cohort profile has been
recently published [25]. From 2006 to 2011, the Phase 1
Central Africa collaboration, in particular, consisted of a total
of 13 facilities providing adult HIV care and treatment (10
adult HIVcare and treatment clinics from Burundi, Cameroon,
and Democratic Republic of Congo (DRC) plus three adult
clinics in Rwanda) and four facilities providing paediatric HIV
care and treatment in Burundi, Cameroon and DRC. Country-
level information on population characteristics and preva-
lence estimates of HIV infection and ART for these four
countries based on the UNAIDS 2008 Report on the Global
AIDS epidemic [2629] are presented in Table 1.
Data were collected and entered at participating health
facilities into separate paediatric and adult databases and
merged at the data coordinating centre at RTI International
in the United States. The collaboration built on the existing
partnerships between the Kinshasa School of Public Health,
RTI International, the University of North Carolina at Chapel
Hill Gillings School of Global Public Health, as well as the
Institute of Tropical Medicine Antwerp, Belgium. Local
collaborators included the HIV/AIDS clinicians/care providers,
representatives of national HIV/AIDS programs, faculty from
medical schools in the region, as well as the International
Center for AIDS Care and Treatment Programs (ICAP) at
Columbia University that contributed data from Rwanda.
The IeDEA-CA clinical cohort
The IeDEA-CA Phase 1 clinical cohort grew from 800 HIV-
positive individuals in 2007 to approximately 22,000 by the
end of 2010: 21,599 adults and 425 children who were
diagnosed as HIV positive. For the purposes of this study, we
focused on the clinics providing adult care and did not
include four participating paediatric care centres, one in DRC,
two in Cameroon and one in Burundi, due to differences in
paediatric and adult cohort characteristics. We also excluded
one site with exclusive care of female patients in Rwanda
because this site differed from the other sites in the IeDEA-
CA consortium in terms of the unique population that it
serves (the majority are survivors of genocidal rape).
Data collection and analysis
Periodic assessments to obtain information on site resources,
facilities, clinical practices, staffing, patient attendance and
care, and additional services or programs offered at the site
were undertaken within the IeDEA-CA collaboration. For the
Table 1. Country population profile and HIV prevalence and treatment characteristics
Burundi Cameroon DR Congo Rwanda
Demographic characteristics
Population (thousands) 8508 18,549 62,636 9725
% of population urban 11 56 33 21
Gross national income per capita ($) (in 2006) 320 2060 270 730
HIV infection and treatment characteristics
Estimated adult HIV prevalence (95% CL)
a 2.0 (1.3, 2.5) 5.1 (3.9, 6.2) 1.2, 1.5 2.8 (2.4, 3.2)
Estimated antiretroviral therapy among clinically eligible
adults (95% CL)
23 (18, 31) 25 (21, 32) 20, 29 71 (62, 84)
Source: UNAIDS 2008 Country HIV/AIDS Epidemiological Profiles.
CL, confidence limits.
a‘Low’ and ‘high’ estimates only reported for DRC.
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2present study, we used responses from a Web-based survey
administered in October 2009 to collect data on (1) site
characteristics including level of care (primary, secondary and
tertiary), staffing characteristics and storage of medical
records; (2) care and treatment characteristics including
points of entry into care and costs incurred by patients for
services; and (3) program characteristics including availability
of clinical and support services, ART availability, patient
follow-up and the diagnosis and management of HIV-
associated illnesses. The survey could be completed directly
online or, for sites with limited internet access, printed and
then entered into the Web-based system. All 12 facilities
included in this analysis completed the survey.
In terms of patient characteristics, sites in the IeDEA-CA
network collected standardized baseline data for each parti-
cipant, as well as follow-up data at subsequent visits. Patients
were followed at regular intervals dictated by their ongoing
care at each local facility. More specifically, patients on ART
were followed every one to three months, and those not
on ART were followed every six months, unless there
was a clinical event for which they needed to return to the
clinic for evaluation and/or care. A facility doctor or nurse
attended all patients. The same data collection forms were
used at participating facilities in Burundi, Cameroon and DRC
to collect data on socio-demographics, anthropometrics,
risk behaviours, medical diagnoses (co-morbidities), labora-
tory values (CD4 counts, viral load, etc.), medications (anti-
retroviral (ARV), cotrimoxazole prophylaxis, TB prophylaxis
and treatment) and dates of initiation, referrals and outcomes
suchasvitalstatusandlosstofollow-up.Datawereabstracted
from the existing electronic database at the participating sites
in Rwanda and harmonized with the IeDEA-CA database. Data
analysis relied predominantly upon descriptive methods and
summary estimates. To enable comparisons between male
and female participants, sex-stratified patient characteristics
are also presented. To facilitate interpretation of these
differences, p values derived from tests of comparison of
the stratified estimates (x
2 test for categorical variables;
Student’s t or median tests for continuous variables) are
presented. The statistical program Stata 12.1 (StataCorp LP,
College Station, TX) was used for all analyses.
Human rights protection
The IeDEA-CA region research project was reviewed by the
Institutional Review Board (IRB) at the Kinshasa School of
Public Health in DRC, the national ethics committees in
Burundi and Cameroon and the data coordinating centre IRB
at RTI International. IRB approval was also obtained from the
Rwanda National Ethics Committee to abstract data from
already existing databases managed by the participating
hospitals and that were made available to the International
Center for AIDS Care and Treatment Programs (ICAP)
at Columbia University and the Rwanda Women’s Inter-
Association Study (RWISA).
Results
Site and program characteristics
The 12 participating adult care sites were a combination of
hospital and ambulatory care units of varying size/capacity,
serving predominantly urban populations, and offering
primary care in DRC, secondary care in Rwanda and tertiary
care in Burundi and Cameroon (Table 2). All sites maintained
on-site electronic databases for data storage and had a
unique identifier for every patient. All sites recorded
patients’ education level and socio-economic status. While
internet availability varied, regular transmissions ensured
that the data coordinating centre database was up-to-date
with the local databases at participating facilities. All sites
documented drug stock-outs and reported some disruption
of ARV medications during the last year, with duration that
varied from one day in Rwanda to more than three weeks in
DRC and Cameroon. All sites indicated that there were
disruptions in prophylactic or opportunistic infection drug
supply in the past year. Provision of routine HIV testing for
patients’ relatives, sex partners and household members
was available in all sites, while some level of linkage to
prevention of mother-to-child transmission (PMTCT) of HIV
programs was also reported. All sites recorded history of
PMTCT for female patients. With the exception of Burundi,
the programs offered nutritional counselling to their patients
and performed frequent anthropometric evaluations. A
summary of program characteristics is presented by country
in Table 2.
Patient characteristics
The IeDEA-CA adult cohort characteristics are presented in
Table 3. DRC had 9871 patients, followed by Cameroon
(n4922), Rwanda (n4583) and Burundi (n2223).
Patients’ mean (median) age ranged from 34 (33) years in
Rwanda to 40 (40) in DRC. Marked differences were evident in
disease status and mean CD4 counts between Rwanda and
DRC, although these estimates were based on small sub-sets
of patients that had CD4 values available. In DRC and
Cameroon, two-thirds of patients were in WHO clinical Stage
III or IVat enrolment into the IeDEA-CA database and virtually
all (97%) of the 3224 patients with clinical stage information
available in the Rwandan sites were in Stage I or II. One-third
of participants in the Rwanda site had missing clinical stage
information, whereas very few of the participants at the sites
in the other three countries had missing clinical stage. More
than half of the patients at the sites in DRC and Rwanda and
80% of the patients at the Burundi sites entered HIV care
through VCT. About two-thirds of patients enrolled in each
country were women though very few entered HIV care
through PMTCTservices in Burundi (3%), Cameroon (4%) and
DRC (0.6%). About one-quarter of the patients in Rwanda
entered HIV care through PMTCT.
With regard to differences between male and female
participants, women were consistently younger (four to eight
years mean difference) than men, in all country programs.
Significantly higher proportions of men were married (i.e.
64% vs. 32% in DRC), while higher proportions of women
were widowed (i.e. 31% vs. 11% in DRC). Women were
enrolled into the IeDEA-CA database at an earlier disease
stage than men, but this difference was most pronounced in
the Cameroon sites. A larger proportion of men entered HIV
care through VCT as compared to women.
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3Treatment regimens
Participating sites in Cameroon were the first within the
IeDEA-CA region to begin offering ART for adults in 2000,
while Rwandan sites started in 200405, and participating
sites in Burundi and DRC between 2006 and 2007 (Table 2). In
the IeDEA participating sites in Burundi and Cameroon,
approximately half of the patients who were enrolled in HIV
care had initiated ART, when the IeDEA-CA baseline form was
completed, whereasthis proportion was one out of four in the
IeDEA sites from DRC. In Rwanda, a small proportion of
patients started ART at the enrolment visit, as this facility
represents a point of entry to HIV care. Although the
participating IeDEA-CA facilities in the other three coun-
tries also represent a point of entry into HIV care, many of
these patients had already been receiving care at these
facilities when the IeDEA-CA database was rolled out.
Table 2. The IeDEA-CA clinical care resources and management practices
Program sites
in Burundi
Program sites
in Cameroon
Program sites
in DR Congo
Program sites
in Rwanda
Electronic infrastructure and documentation
Availability of internet for the support staff
(percent of time)
80 100 0
b 100
Availability of internet for the clinical staff
(percent of time)
50 50
a 0
b 100
e
Record a national IDF or government ID for every
patient
No No
a No
c Yes
Possible to link a patient’s records to a child’s
records
No No Yes
d Yes
e
Possible to link a patient’s records to a spouse or
partner’s records
No No No
b Yes
e
What CD4 criteria are used for ART initiation at each
WHO stage?
WHO 1 B350 B350 B200 B350
WHO 2 B350 B350 B200 B350
WHO 3 Any B200 B350 B350
WHO 4 Any Any Any Any
Monitoring and availability of drugs/services
Disruptions of ARV drug supply in the past year Yes Yes Yes No
How long was the worst disruption in ARV drug
supply in the last six months?
Two to seven
days
 21 days  21 days One day
Relationship of HIV with PMTCT programs Both on-site
and linked
Both on-site
and linked
a
PMTCT program is off-site
and linked to care and
treatment program
c
Both on-site
and linked
Provision of nutritional counseling No Yes Yes
c Yes
Frequency of anthropometric evaluation
for adult patients
Not done Once every
three months
Every one to three
months
Once a month
Costs incurred by patients for services
Screening consult No (free) Full pay
a No (free) No (free)
Laboratory tests No (free) Partial pay
a Partial pay
d No (free)
Diagnostic exams Partial pay Full pay No (free)
b No (free)
e
First-line ART No (free) No (free) No (free) No (free)
Second-line ART No (free) No (free) No (free) No (free)
OI prophylaxis Partial pay No (free)
a No (free)
b No (free)
OI treatment Partial pay Full pay No (free)
b No (free)
e
Routine follow-up consult No (free) Full pay
a No (free) No (free)
Viral load tests No (free) Full pay Full pay No (free)
ART, antiretroviral therapy; ARV, antiretroviral drugs; IeDEA-CA, International Epidemiologic Databases to Evaluate AIDS Central Africa; IDF/ID,
identification document; OI, opportunistic infection; PMTCT, prevention of mother-to-child transmission of HIV; WHO, World Health
Organization.
aDenotes in 2/3 sites in Cameroon;
b5/6 sites,
c4/6 sites,
din 3/6 sites in DR Congo;
ein 1/2 sites in Rwanda.
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4Table 3. The IeDEA-CA adult clinical cohort characteristics by country, overall and stratified by sex
Program sites in Burundi Program sites in Cameroon Program sites in DR Congo Program sites in Rwanda
Number of sites 1 3 6 2
Number of adult patients (n) 2223 4922 9871 4583
Sex
Female, n (%)
a 1536 (69) 3437 (70) 6726 (68) 3095 (68)
Male, n (%)
a 686 (31) 1482 (30) 3096 (32) 1488 (32)
Missing, n 1 3 49 0
All (%)
a Female (%) Male (%) p
b All (%)
a Female (%) Male (%) p
b All (%)
a Female (%) Male (%) p
b All (%)
a Female (%) Male (%) p
b
Socio-demographics
Age (years; mean) 38 36 42 B0.05
c 38 37 41 B0.05
c 40 38 43 B0.05
c 34 32 38 B0.05
c
Marital status
Married 35 28 52 33 24 53 42 32 64 30 25 41
Single/living together but
not married
32 33 31 B0.05 47 51 36 B0.05 23 25 19 B0.05 53 54 51 B0.05
Divorced 9 11 7 5 6 3 11 13 7 2 2 1
Widowed 23 28 11 16 19 7 24 31 11 15 19 7
Missing (n) 1 1 0 0 0 0 415 296 96 1876 1315 561
Perceived discordancy with
partner
Yes 7 6 10 B0.05 20 17 26 B0.05 8 7 11 B0.05 30 27 38 B0.05
No 35 29 50 23 20 30 23 21 28 13 10 17
Do not know 16 18 12 32 33 29 46 47 45 12 14 7
N/A or missing 41 46 28 25 30 15 23 26 16 45 49 38
Pregnant
Yes 4 4 3 15
No 96 96 97 85
Missing (n)2 0 4 7 0
Clinical characteristics
WHO Clinical Stage
I 33 33 33 0.10 16 17 12 B0.05 9 10 8 0.09 64 67 59 B0.05
II 17 17 16 19 20 18 24 24 24 33 31 36
III 36 37 34 50 50 52 61 61 61 3 2 5
IV 14 13 17 15 13 18 6 6 6 0 0 0
Missing (n) 7 4 2 17 8 6 125 73 31 1359 830 529
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5Table 3 (Continued)
All (%)
a Female (%) Male (%) p
b All (%)
a Female (%) Male (%) p
b All (%)
a Female (%) Male (%) p
b All (%)
a Female (%) Male (%) p
b
CD4 count (median) 318 253 B0.05
d 219 182 B0.05
d 235 187 B0.05
d 440 306 B0.05
d
missing (n) 700 323 861 611 248 8009 5418 2556 3823 2560 1263
ART
Initiated prior to enrolment 50 52 43 B0.05 49 49 47 0.62 27 28 27 0.57 0.1 0.2 0 0.19
Initiated at enrolment 5 5 7 36 36 38 2 1 2 6 5 6
Stopped at enrolment 1 0.8 0.3 0.1 0.1 0.1 0.4 0.4 0.4 0 0 0
Never (ART-naı ¨ve) 44 42 50 15 15 15 71 70 71 94 94 94
Missing (n) 8 6 1 18 9 6 133 75 35 0 0 0
Entry to HIV care
VCT 81 79 84 B0.05 40 39 42 B0.05 56 56 57 B0.05 55 50 67 B0.05
PMCTC 3 4 0 4 6 0.3 0.6 0.8 0.2 24 31 9
TB/STI clinic or other 14 14 13 32 30 35 10 10 9 21 19 24
No previous care 3 3 3 25 25 23 33 33 33 0 0 0
Missing (n) 71 50 21 3 0 0 93 46 21 0 0 0
TB therapy
Yes 4 3 7 B0.05 5 4 6 B0.05 5 5 6 B0.05 0.1 0.1 0.1 0.97
No 96 97 93 95 96 94 95 95 94 100 100 100
Missing (n) 8 6 1 8 3 2 124 68 28 0 0 0
ART, antiretroviral therapy; IeDEA-CA, International Epidemiologic Databases to evaluate AIDS Central Africa; IQR, interquartile range; PMTCT, prevention of mother-to-child transmission of HIV; SD,
standard deviation; STI, sexually transmitted infection; TB, tuberculosis; VCT, voluntary counseling and testing for HIV prevention; WHO, World Health Organization.
aPercentages calculated among the non-missing responses;
bp values derived from x
2 tests of equivalence;
cStudent’s t-test of equality of means;
dtest of equality of medians.
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6The most common treatment regimen was d4T-303TC
NVP (stavudine/lamivudine/nevirapine64%), followed by
AZT3TCNVP (zidovudine/lamivudine/nevirapine19%).
Approximately one-third of patients had a drug substitution
in Cameroon, whereas this proportion was smaller in Burundi
(25%) and in DRC (15%). Four percent of patients underwenta
change from first to second line regimens in Cameroon and
Burundi, and less than 1% in DRC.
Discussion
The unique challenges of HIV care in sub-Saharan Africa
require a ‘‘systems approach’’ based on operational research
and a solid evidence-base [30,31]. Gaining a pragmatic
and comprehensive understanding of the current HIV
care characteristics in the region is a pre-requisite for any
intervention or ‘‘fine-turning’’ of current practices, re-
allocation of resources or other programmatic changes. The
data presented here provide insights into HIV care within the
Central Africa region and can set the stage for additional
hypothesis-generating research and subsequent longitudinal
investigations. It is imperative, however, that these observa-
tions are considered in the context of regional and country-
level framing factors, to gain understanding into possible
program-implementation gaps and differences [32].
Between-country and -site differences: structural barriers
to ART
Country-level differences that frame HIV care are evident in
the domains of urban/rural population ratio (e.g. Burundi:
11% vs. Cameroon: 56%), the estimated prevalence of HIV
infection (DRC: 1.21.5% vs. Cameroon: 5.1%) and the
proportion of eligible adults receiving ART (approximately
20% for all countries except Rwanda: 71%) [2629]. Serious
challenges have been reported in the implementation phase
of ART programs in the region, and among those are
important structural, health system, social and behavioural
barriers to ART initiation and adherence [33,34]. According to
recent reports, the availability and adequacy of human
resources in the health sector has been a major ART
implementation impediment in Burundi [35], whereas de-
centralization, HIV testing and referrals, and ARV supply have
been additional structural barriers in Cameroon [3638].
Conversely, Rwanda has often been regarded as an example
of successful build-up of health system infrastructures and
decentralization of services across the country [39].
Studies based on quantitative [40] and qualitative [41,42]
methodology have provided valuable insights into the multi-
level factors affecting patients’ access to, initiation, and
adherence to ART in the region. ‘‘Common themes’’ include
patients’ difficulty accessing HIV care sites due to distance,
work and long waiting lines [41,43,44], health personnel
number and training inadequacies [45], infrastructure insuf-
ficiencies [46], poverty [47], migration [48] and others.These
factors (e.g. distance to the clinic) are important parameters
when one considers the catchment population of the
participating facilities, which served exclusively urban popu-
lations in Rwanda and DRC (with the exception of one site)
and both urban and rural in Burundi and Cameroon. They
also need to be taken into consideration when comparing the
demographic and clinical profile of each country’s cohort (i.e.
compared to patients in the DRC sites, those followed in the
Rwandan facilities had a seven-year younger median age and
most were in WHO Stage I vs. III in DRC). Noteworthy, the
large differences that were observed in ART initiation status
and CD4 counts were affected by country characteristics,
but also by each site’s reference population (rural/urban),
entry to HIV care and more.
Noteworthy, all sites used the then-current WHO criteria
for ART initiation and treatment was offered free of charge to
patients. Of course, entry to HIV care is of paramount
importance, as recent findings among HIV-infected patients
in sub-Saharan Africa [49] indicate that much of the excess
mortality experienced among seropositive patients might be
prevented by more timely initiation of ART.
Rwanda is the only country where participating IeDEA sites
reported no ARV drug stock-outs and supply interruptions in
the past year. This is an important finding, as hospital phar-
macy ARV shortage was identified as a significant predictor
of ART non-adherence among a sample of Cameroonian
patients, in Yaounde ´ [40]. As mentioned above, patients
enrolled in Rwanda were younger, tended to be enrolled into
care at WHO clinical Stage I or II and had, acknowledging the
missing data issue, higher CD4 counts. This observation,
although limited by the non-representativeness of the study
sample, is consistent with the high ART-enrolment proportion
in Rwanda  a PEPFAR-focus country, and the only focus
country among our Central Africa cohort. Rwanda is one of
eight low- and middle-income countries (and one of only two
in Africa) that had achieved universal access to ART by
December 2009 [50]. In 2008, PEPFAR was re-authorized
with funds of nearly $50 billion and included a focus on
strengthening existing health systems [20,51].
By-sex differences
Because sex-related disparities in HIV care are commonly
reported [52,53], the presentation of sex-stratified patient
characteristics of the IeDEA-CA clinical cohort is of interest.
For example, recent data among HIV-infected individuals
under care showed that women may experience higher
mortality than men, even after controlling for HAART
utilization [54]. In the current study, a larger proportion of
men presented with Stage IV disease in sites in Cameroon
and Burundi and had lower CD4 counts in all sites, which is
consistent with other recent findings [55]. This, along with
the observed demographic differences (men were older and
more likely to be married), can be attributed to men’s delay
in seeking HIV care. Similarly, men’s higher access via VCT
may be due to their experience of disease symptoms, or self-
definition as being at risk for HIV infection. More research is
required to disentangle the contribution of social, cultural,
behavioural, or biological and immunological factors [5659]
to these by-sex differences.
Strengths and limitations
The main strength of the IeDEA-CA is the cohort’s large
number of seropositive individuals for whom socio-demo-
graphic and anthropometric data, clinical values, co-morbid
conditions and treatment status were available. Moreover,
the participating facilities benefited from the harmonization
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7efforts in data collection, the quality assurance proce-
dures and the improved data collection and management.
As an example, many of the participating sites in Burundi,
Cameroon and DRC began to use the IeDEA-CA data
collection forms as the medical charts for patient care and
the accompanying database as the electronic medical record
system [60]. A reporting tool, available to each facility
completing the IeDEA-CA forms, enabled physicians to
produce reports by key variables (i.e. gender and ARV
regimens) which were useful for clinic management, fulfilling
reporting requirements for funding agencies and producing
enrolment graphs for presentations and other advocacy
activities. A listing of study ID numbers can be produced
for patients that have not returned to clinic for scheduled
appointments assisting clinic staff with lost to follow-up
tracking. Prior to the IeDEA-CA database and accompanying
reporting tool, many physicians and staff at the participating
health facilities in Cameroon, Burundi and DRC were
spending large amounts of time tallying these reports
manually, which took away from patient care. However,
patient management issues such as loss to follow-up remain
a priority area for improvement.
While the IeDEA-CA adult HIV clinical care characteristics
presented in this article reflect the participating facilities’
characteristics and patients’ profile, these data are neither
nationally representative nor derived from randomly selected
HIV care facilities; therefore, they lack the external validity
that would permit between-country comparisons and infer-
ences. Data completeness is another major limitation. For
example, there were considerable proportions of missing
information for marital status in DRC and Rwanda. Moreover,
we have substantial proportions of missing information on
patients’ clinical stage, mainly in Rwanda, and CD4 counts,
mainly in DRC, but also in Burundi and Rwanda.The extent of
missing data is a reflection of systematic between-site
differences, including enrolled patients’ characteristics and
stage of disease/treatment; however, disentangling these
influences is not possible from these data. Additionally, the
cohort faces the threats that all open clinical cohorts
encounter, in terms of patient retention. The problem of
substantial number of patients on ART being lost to follow-up
in resource-limited settings has been well-documented, and
measures to maximize ART program retention are warranted
[61]. All participating IeDEA-CA sites had protocols for
contacting and documenting the outcomes of those lost to
follow-up.
Although, according to data of the last decade, small
proportions of HIV-infected individuals actually received
treatment in the Central Africa region, ranging from 2% to
26%, the more than 20,000 HIV-positive individuals that are
followed in IeDEA-CA network facilities represent a consider-
able cohort. Nevertheless, more efforts are needed in the
region to step-up efforts to provide treatment to all
individuals that are in need of it.
Conclusions
The information presented in this paper outlines and
provides insight into the program, site and patient char-
acteristics with regard to HIV adult clinical care in selected
facilities in Burundi, Cameroon, DRC and Rwanda.This robust
cohort of more than 22,000 seropositive individuals demon-
strates the feasibility of establishing large clinical cohorts of
HIV-positive individuals in a relatively short amount of time
in spite of challenges experienced by clinics in resource-
limited settings such as those in this region. Within its
limitations, the IeDEA-CA network provides a unique frame-
work for data collection harmonization and quality assurance,
while offering a plethora of research opportunities that
facilitate collaborative initiatives in the region. It is envi-
sioned that the development of future research initiatives
and additional program activities will enhance adult care HIV
treatment in Central Africa and beyond.
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